Vimarsana
Biggest News Aggregation in the World

Page 21 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene, Ltd. Expected to Post FY2027 Earnings of $5.40 Per Share (NASDAQ:BGNE) - Vimarsana News

BeiGene, Ltd. Expected to Post FY2027 Earnings of $5.40 Per Share (NASDAQ:BGNE)

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) – Analysts at SVB Leerink issued their FY2027 earnings per share (EPS) estimates for BeiGene in a research report issued to clients and investors on Tuesday, April 25th. SVB Leerink analyst A. Berens forecasts that the company will post earnings per share of $5.40 for the year. SVB Leerink […]

BEIGENE, LTD. : Stock Market News and Information | BGNE| US07725L1026 - Vimarsana News

BEIGENE, LTD. : Stock Market News and Information | BGNE| US07725L1026

BEIGENE, LTD. : News, information and stories for BEIGENE, LTD. | Nasdaq: BGNE | Nasdaq

BeiGene : Financial Information - Form 8-K - Vimarsana News

BeiGene : Financial Information - Form 8-K

Financial Information On April 25, 2023, BeiGene, Ltd. filed the 2022 Annual Report with the Science and Technology Innovation Board of the Shanghai Stock... | April 25, 2023

Simplicity Solutions LLC Grows Stock Position in BeiGene, Ltd. (NASDAQ:BGNE) - Vimarsana News

Simplicity Solutions LLC Grows Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)

Simplicity Solutions LLC grew its position in BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) by 6.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,527 shares of the company’s stock after purchasing an additional 202 shares during the period. Simplicity Solutions LLC’s holdings in BeiGene were […]

Source: wkrb13.com
Tislelizumab Plus Chemotherapy Meets OS End Point in Advanced Gastric/GEJ Adenocarcinoma - Vimarsana News

Tislelizumab Plus Chemotherapy Meets OS End Point in Advanced Gastric/GEJ Adenocarcinoma

The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.